GIP and Hyperglycemia: Therapeutic approaches are aimed at decreasing postprandial hyperglycemia mainly by the inhibition of dipeptidyl peptidase-IV (DPP-IV), which degrades and inactivates the incretin hormones glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide.